| scholarly article | Q13442814 |
| P2093 | author name string | Gail A Van Norman | |
| P2860 | cites work | Angiotensin-neprilysin inhibition versus enalapril in heart failure | Q28247091 |
| Key cost drivers of pharmaceutical clinical trials in the United States | Q28273573 | ||
| Estimating the cost of new drug development: is it really 802 million dollars? | Q28300812 | ||
| Profitability and Market Value of Orphan Drug Companies: A Retrospective, Propensity-Matched Case-Control Study | Q28552860 | ||
| How were new medicines discovered? | Q29616641 | ||
| Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association | Q30238784 | ||
| Chronic diseases: the emerging pandemic. | Q30404279 | ||
| Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma | Q33369050 | ||
| Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. | Q34089761 | ||
| Pricing and reimbursement of orphan drugs: the need for more transparency | Q34193502 | ||
| Diagnosing the decline in pharmaceutical R&D efficiency | Q34257771 | ||
| How innovative are new drugs launched in the UK? A retrospective study of new drugs listed in the British National Formulary (BNF) 2001-2012 | Q34417204 | ||
| Multidrug-resistant tuberculosis and culture conversion with bedaquiline. | Q34434294 | ||
| Drug-review deadlines and safety problems | Q34764725 | ||
| How a patient advocacy group developed the first proposed draft guidance document for industry for submission to the U.S. Food and Drug Administration | Q35801586 | ||
| Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study | Q36087521 | ||
| Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009. | Q37824591 | ||
| FDA designations for therapeutics and their impact on drug development and regulatory review outcomes. | Q38351467 | ||
| Cardiovascular drug development: is it dead or just hibernating? | Q38424497 | ||
| Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial | Q38441000 | ||
| Innovative Clinical Trial Designs for Precision Medicine in Heart Failure with Preserved Ejection Fraction | Q38691846 | ||
| Efficient design of clinical trials and epidemiological research: is it possible? | Q38817527 | ||
| Occlusion in the Flow of New Drugs for Cardiovascular Disease. | Q39221282 | ||
| Late-stage pharmaceutical R&D and pricing policies under two-stage regulation | Q39253732 | ||
| Evaluation of Therapeutics for Advanced-Stage Heart Failure and Other Severely-Debilitating or Life-Threatening Diseases. | Q39285539 | ||
| Challenges in the Development of Novel Cardiovascular Therapies | Q39393735 | ||
| New approach to clinical trials and drug registration. Author's suggestions for drug approval are questionable | Q42018848 | ||
| 2013 FDA drug approvals | Q44117034 | ||
| Regulatory Consequences of "Brexit" for the Development of Medicinal Products | Q47318390 | ||
| Why it won't happen to me: perceptions of risk factors and susceptibility. | Q51237042 | ||
| Affairs of the Heart: Innovation in Cardiovascular Research and Development. | Q53157206 | ||
| Market watch: Are orphan drug companies the pick of the pharmaceutical industry? | Q87016048 | ||
| Era of faster FDA drug approval has also seen increased black-box warnings and market withdrawals | Q87504444 | ||
| Intelligent pharmaceuticals: beyond the tipping point | Q87711989 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 613-625 | |
| P577 | publication date | 2017-10-30 | |
| P1433 | published in | JACC. Basic to Translational Science | Q27727237 |
| P1476 | title | Overcoming the Declining Trends in Innovation and Investment in Cardiovascular Therapeutics: Beyond EROOM's Law | |
| P478 | volume | 2 |
| Q90356659 | Identification of amitriptyline HCl, flavin adenine dinucleotide, azacitidine and calcitriol as repurposing drugs for influenza A H5N1 virus-induced lung injury |
| Q64081820 | Overcoming Barriers to Development of Novel Therapies for Cardiovascular Disease |
| Q92619713 | Permeability of Epithelial/Endothelial Barriers in Transwells and Microfluidic Bilayer Devices |
| Q91943657 | Phase II Trials in Drug Development and Adaptive Trial Design |
Search more.